AmeriPath Announces the Appointment of Michael W. Robles, D.O., as Director of Gastrointestinal Pathology, AmeriPath North Texas.

PALM BEACH GARDENS, Fla. -- AmeriPath, Inc. ("AmeriPath") a leading national provider of anatomic pathology, dermatopathology, and molecular diagnostics services to physicians, hospitals, clinical laboratories, and surgery centers, is pleased to announce the appointment of Michael W. Robles, D.O., as Director of Gastrointestinal Pathology, AmeriPath North Texas. In this leadership role, he will focus on the continuing development of AmeriPath North Texas' testing services used by referring physicians in the detection, diagnosis, and treatment of GI and digestive disorder-related diseases.

Dr. Robles will head the current team of GI-specialized pathologists at AmeriPath North Texas, focusing primarily on GI histological services, consultations on difficult cases, and esoteric testing to assist physicians in the diagnosis and management of GI and digestive diseases. Prior to his appointment, Dr. Robles had the privilege of serving as a Robert E. Petras fellow at AmeriPath's Institute of Gastrointestinal Pathology and Digestive Disease, Cleveland, Ohio. During his fellowship, Dr. Robles' professional development was tailored through intensive, individualized instruction; participation in a wide-ranging GI pathology consultation practice; and assistance in the management of a thriving GI pathology outpatient practice.

Stephen W. Aldred, M.D., AmeriPath's West Regional President, commented, "We are indeed pleased and honored that Dr. Michael Robles has joined us at AmeriPath North Texas as Director of Gastrointestinal Pathology at the Alpha Road facility. He joins us after having completed a rigorous GI pathology fellowship with Dr. Robert Petras at the AmeriPath GI Institute. As a physician-driven organization, we understand the needs of clinicians and the importance of providing specialists in their local communities. This is what will distinguish AmeriPath from its competition in the future. Our focus continues to be on the local placement of highly qualified GI pathologists, reinforced by the resources of a national company, in order to achieve and maintain a truly unparalleled record of excellence in support of the medical communities and the patients we serve. Again, please welcome Dr. Robles to AmeriPath North Texas."

Dr. Robles graduated from the School of Osteopathic Medicine, University of Medicine and Dentistry of New Jersey. He went on to do a residency in anatomic and clinical pathology, with training at both the University of California, Irvine, and Cedars-Sinai Medical Center, Los Angeles. As Chief Resident at the University of California, Irvine, Dr. Robles played a key role in the planning and conduct of resident training and participated in interdisciplinary tumor boards and medical conferences. Upon concluding his residency, Dr. Robles accepted the position of Surgical Pathology Fellow, University of Texas Southwestern Medical Center, Dallas. During the term of his fellowship, he solidified his training in anatomic pathology with full sign-out authority, participation in GI tumor boards, and the administration of resident training and development.

Dr. Stephen Jolissaint, Medical Director of AmeriPath North Texas, stated, "We are extremely pleased that Dr. Michael Robles has joined our AmeriPath North Texas team and that he will be providing high-level interpretive skills and administrative direction for GI pathology. His fellowship training and professional growth at AmeriPath will serve to bring unique new approaches to the diagnosis and management of GI diseases and will reaffirm AmeriPath's vision of providing high-quality GI pathology services to our referring physicians."

About AmeriPath, Inc.:

AmeriPath, a leading national provider of physician-based anatomic pathology, dermatopathology, and molecular diagnostic services to physicians, hospitals, clinical laboratories, and surgery centers, supports community-based medicine by helping physicians provide optimal patient care. Our team of subspecialized pathologists and doctoral-level scientists provides medical expertise, diagnostic quality, and personal consultation services. AmeriPath's elite team of more than 400 highly trained, board-certified pathologists provides medical diagnostics services in outpatient laboratories that are owned, operated, and managed by AmeriPath, as well as in hospitals and ambulatory surgical centers. AmeriPath's Web site is www.ameripath.com.

About Specialty Laboratories, Inc.:

Specialty Laboratories supports local pathology and community-based medicine by partnering with pathologists and hospitals to improve patient care and reduce episodes-of-care costs. Specialty offers hospitals an extensive menu of highly advanced clinical tests used by physicians to diagnose, monitor, and treat disease and a single-source solution for esoteric testing needs. Specialty's Web address is www.specialtylabs.com.

The above statements include forward-looking statements based on current management expectations. Such statements are sometimes identified by words such as "may," "should," "believe," "expect," "anticipate," "estimate," "project," and similar expressions and may include financial or operating estimates, forecasts, or projections. Numerous factors exist which may cause results to differ materially from these expectations. Many of the factors that will determine the Company's future results are beyond the ability of the Company to control or predict and these forward-looking statements are subject to risks and uncertainties relating to the Company, including without limitation (i) possible changes in reimbursement rules under government and third-party health care programs and the payments received under such programs, (ii) the Company's ability to attract, motivate, and retain pathologists and senior management, (iii) risks associated with the Company's acquisition strategies, including without limitation the successful completion and integration of acquisitions (and achievement of planned or expected synergies) and the availability of pathology practices in appropriate locations that the Company is able to acquire on suitable terms or develop, (iv) federal and state health care regulation (and compliance), (v) changes in coding, (vi) the highly competitive nature of the health care business, and (vii) those risks and uncertainties detailed from time to time in the Company's filings with the SEC. Therefore, the Company's actual results may differ materially. The Company undertakes no obligation to update any forward-looking statements or to make any other forward-looking statements, whether as a result of new information, future events, or otherwise.